Skip to content
Platform
Programs
People
News
Join Us
Contact Us
Menu
Platform
Programs
People
News
ALTA3263
August 22, 2024
More
October 30, 2024
Alterome Therapeutics Announces First Patient Dosed in Phase 1 Study of ALTA2618 in AKT1 E17K-mutant solid tumors (AKTive-001)
October 25, 2024
Alterome Therapeutics to Present Preclinical Data for its KRAS Selective Inhibitor ALTA3263 at the 2024 ENA Symposium